Pharmaceutical products; requiring manufacturers to publish certain list of ingredients; providing administrative, civil, and criminal penalties and remedies. Effective date.
Impact
The bill proposes significant changes to how pharmaceutical products are regulated at the state level. By requiring detailed ingredient disclosures, it aims to empower consumers and enhance public health safety. Furthermore, the legislation empowers the State of Oklahoma to enforce compliance through a variety of administrative, civil, and even criminal penalties for noncompliance. This shift could lead to a more responsible and accountable pharmaceutical sector, thereby potentially reducing health risks associated with undisclosed or poorly understood ingredients.
Summary
Senate Bill 941 seeks to enhance transparency in the pharmaceutical industry by mandating that manufacturers disclose a comprehensive list of ingredients for all pharmaceutical products, including prescription drugs, over-the-counter medications, and vaccines. The legislation also emphasizes the inclusion of ingredients derived from biological sources, such as mRNA and DNA, providing detailed information regarding their origins and purposes. This level of disclosure is aimed at informing consumers and ensuring that they are aware of what is included in the medications they use.
Executive
The bill also highlights the importance of maintaining rights during declared national emergencies, ensuring that ingredient disclosure requirements remain in effect regardless of the circumstances. This aspect of the legislation is intended to protect the public interest and uphold transparency even during times of crisis, reflecting a commitment to consumer safety and informed health decisions.
Contention
However, SB941 is rooted in controversy, particularly regarding its implications for manufacturers. Opponents argue that the stringent requirements could increase operational costs, resulting in higher prices for consumers and possibly limiting access to essential medications. Additionally, there are concerns about the potential for increased litigation against manufacturers due to the private right to civil action for any alleged misrepresentation or omission of ingredient information, which could overwhelm the judicial system and create a chilling effect on pharmaceutical innovation.
Carry Over
Pharmaceutical products; requiring manufacturers to publish certain list of ingredients; providing administrative, civil, and criminal penalties and remedies. Effective date.
Pharmaceutical products; requiring manufacturers to publish certain list of ingredients; providing administrative, civil, and criminal penalties and remedies. Effective date.
Practice of pharmacy; requiring licensure of certain out-of-state pharmacies; requiring certain inspections; providing administrative remedies and penalties. Effective date.
Health care; creating the Vaccine Transparency and Informed Consent Act; requiring certain informed consent; providing certain penalties and remedies. Effective date.
Schools; requiring school districts and charter schools to submit certain list of library materials; providing process for reporting violations; providing penalties. Effective date. Emergency.